Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.76 - $39.56 $2.15 Million - $2.6 Million
-65,661 Reduced 6.86%
891,220 $31.2 Million
Q4 2023

Feb 14, 2024

SELL
$14.5 - $38.0 $28,985 - $75,962
-1,999 Reduced 0.21%
956,881 $36.4 Million
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $296,070 - $485,653
17,457 Added 1.85%
958,880 $24.9 Million
Q1 2023

May 15, 2023

SELL
$18.45 - $27.14 $3.65 Million - $5.37 Million
-197,914 Reduced 17.37%
941,423 $17.8 Million
Q4 2022

Feb 14, 2023

SELL
$20.18 - $33.33 $4.03 Million - $6.66 Million
-199,690 Reduced 14.91%
1,139,337 $28.1 Million
Q3 2022

Nov 14, 2022

SELL
$11.58 - $24.73 $847,760 - $1.81 Million
-73,209 Reduced 5.18%
1,339,027 $24 Million
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $1.05 Million - $3.1 Million
122,763 Added 9.52%
1,412,236 $16 Million
Q1 2022

May 16, 2022

BUY
$19.89 - $43.18 $431,871 - $937,567
21,713 Added 1.71%
1,289,473 $28.7 Million
Q4 2021

Feb 14, 2022

SELL
$26.75 - $46.02 $3.15 Million - $5.42 Million
-117,882 Reduced 8.51%
1,267,760 $55.4 Million
Q3 2021

Nov 15, 2021

SELL
$25.18 - $37.81 $1.49 Million - $2.24 Million
-59,188 Reduced 4.1%
1,385,642 $46.2 Million
Q2 2021

Aug 16, 2021

SELL
$14.69 - $27.52 $1.29 Million - $2.42 Million
-87,957 Reduced 5.74%
1,444,830 $39.8 Million
Q1 2021

May 17, 2021

SELL
$16.27 - $41.26 $382,865 - $970,930
-23,532 Reduced 1.51%
1,532,787 $30.8 Million
Q4 2020

Feb 16, 2021

BUY
$15.96 - $50.0 $16.9 Million - $52.8 Million
1,056,593 Added 211.43%
1,556,319 $51.3 Million
Q3 2020

Nov 16, 2020

BUY
$16.77 - $20.65 $8.38 Million - $10.3 Million
499,726 New
499,726 $9 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Arrow Mark Colorado Holdings LLC Portfolio

Follow Arrow Mark Colorado Holdings LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.